Researchers at Tongji Medical College and Huazhong University of Science and Technology have mapped the latest victories and future directions of cancer cell therapy. In solid‑tumor treatment, the experimental CAR‑T drug satri‑cel, which targets the protein Claudin‑18.2, doubled the time patients with advanced stomach cancer lived without disease progression in a landmark Phase II trial, cutting the risk of tumor growth by 63% and positioning it as a likely third‑line standard. Another CAR‑T product, C‑CAR031, aimed at GPC3, achieved a 57% response rate in high‑dose patients, while a CD70‑targeted CAR‑T showed strong results in kidney cancer. TCR‑T cells, which can recognize hidden tumor markers inside cells, earned the FDA’s first approval for synovial sarcoma in August 2024, and therapies against NY‑ESO‑1 and MAGE‑A4 are delivering impressive outcomes across several solid cancers. The first FDA‑fast‑track TIL therapy, lifileucel (Amtagvi), received approval for melanoma that no longer responds to PD‑1 blockers, showing a 31.5% response rate and even complete lung‑metastasis regressions when paired with PD‑1 inhibitors. Next‑generation approaches are also emerging. Off‑the‑shelf CAR‑NK cells, which avoid graft‑versus‑host disease, have produced response rates above 70% in B‑cell cancers and over 60% remission in acute myeloid leukemia. CAR‑macrophages (CAR‑M) are being tested to turn “cold” tumors into “hot” ones, with early trials reporting disease stability in nearly a third of patients. To cut costs and speed delivery, scientists are now engineering CAR genes directly inside patients using viral vectors or lipid nanoparticles—an “in‑body” CAR‑T that achieved a 100% response in a tiny multiple‑myeloma study. Stem‑cell platforms add another layer: iPSC‑derived CAR‑NK cells (FT596) hit a 64% response in B‑cell lymphoma, and engineered mesenchymal stem cells are being used as living carriers for drugs, viruses, and even CAR molecules. Looking ahead, the field will lean on AI for toxicity warnings, CRISPR to boost T‑cell stamina, and 3D organoid models to fast‑track new designs. With these tools, cell therapy aims to become safer, more effective, and widely available, offering fresh hope to cancer patients worldwide.
Read more